Genetic
PF-06939926
PF-06939926 is a genetic therapy with 3 clinical trials. Currently 1 active trials ongoing.
Total Trials
3
Max Phase
—
Type
GENETIC
Molecule
—
Success Metrics
Completion Rate
0%(0/2)
Active Trials
1(33%)
Terminated
2(67%)
Phase Distribution
Ph phase_1
1
33%
Ph phase_3
1
33%
Ph phase_2
1
33%
Phase Distribution
1
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution3 total trials
Phase 1Safety & dosage
1(33.3%)
Phase 2Efficacy & side effects
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
0.0%
0 of 2 finished
Non-Completion Rate
100.0%
2 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Terminated(2)
Detailed Status
Terminated2
Active, not recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
0.0%
Most Advanced
Phase 3
Trials by Phase
Phase 11 (33.3%)
Phase 21 (33.3%)
Phase 31 (33.3%)
Trials by Status
active_not_recruiting133%
terminated267%
Recent Activity
1 active trials
Showing 3 of 3
active_not_recruitingphase_3
Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy
NCT04281485
terminatedphase_2
Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy
NCT05429372
terminatedphase_1
A Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular Dystrophy
NCT03362502
Clinical Trials (3)
Showing 3 of 3 trials
NCT04281485Phase 3
Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy
NCT05429372Phase 2
Study of Fordadistrogene Movaparvovec in Early Stage Duchenne Muscular Dystrophy
NCT03362502Phase 1
A Study to Evaluate the Safety and Tolerability of PF-06939926 Gene Therapy in Duchenne Muscular Dystrophy
All 3 trials loaded
Drug Details
- Intervention Type
- GENETIC
- Total Trials
- 3